

Metabolic Manipulation in chronic heart failure

Submission date 19/05/2010	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered <input checked="" type="checkbox"/> Protocol
Registration date 19/05/2010	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results
Last Edited 01/10/2018	Condition category Circulatory System	<input type="checkbox"/> Individual participant data

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Dr Roger Beadle

Contact details
Edgbaston
Birmingham
United Kingdom
B15 2TT

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number
NCT00841139

Secondary identifying numbers
3741

Study information

Scientific Title

Metabolic changes induced by perhexiline versus placebo on myocardial metabolism in chronic heart failure: a multicentre randomised interventional treatment trial

Study objectives

We wish to investigate the metabolic changes induced by perhexiline on myocardial metabolism in chronic heart failure. Perhexiline has been shown to improve exercise capacity in this group of patients. Perhexiline is thought to work by increasing carbohydrate metabolism and reducing fatty acid metabolism leading to improved metabolic efficiency. We plan to investigate myocardial metabolism both invasively and non-invasively to demonstrate these changes.

Ethics approval required

Old ethics approval format

Ethics approval(s)

South Birmingham REC approved on the 12th May 2006 (ref: 06/Q2707/7)

Study design

Multicentre randomised interventional treatment trial

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Study setting(s)

Hospital

Study type(s)

Treatment

Participant information sheet

Not available in web format, please use the contact details below to request a patient information sheet

Health condition(s) or problem(s) studied

Topic: Cardiovascular; Subtopic: Cardiovascular (all Subtopics); Disease: Cardiovascular

Interventions

Perhexiline/Placebo 100 mg orally twice daily (bd) randomised in a 50:50 fashion with drug dose titration in accordance with serum levels.

Total duration of follow-up: one month

Intervention Type

Other

Phase

Not Applicable

Primary outcome measure

Improvement in PCr/ATP ratio

Secondary outcome measures

1. Change in mechanical efficiency (external work/ MVO₂)
2. Change in respiratory quotient

Overall study start date

04/09/2006

Completion date

04/09/2009

Eligibility**Key inclusion criteria**

1. Aged greater than 18 years, no upper limit, either sex
2. Optimally medicated dilated cardiomyopathy
3. Symptomatic (New York Heart Association [NYHA] II - III)
4. Ejection fraction (EF) less than 40%

Participant type(s)

Patient

Age group

Adult

Lower age limit

18 Years

Sex

Both

Target number of participants

Planned sample size: 50

Key exclusion criteria

1. Implanted cardiac devices
2. Body mass index (BMI) greater than 32
3. Renal impairment
4. Liver function test abnormalities
5. Use of amiodarone
6. Selective serotonin reuptake inhibitor (SSRI) medications or haloperidol

Date of first enrolment

04/09/2006

Date of final enrolment

04/09/2009

Locations

Countries of recruitment

England

United Kingdom

Study participating centre

Edgbaston

Birmingham

United Kingdom

B15 2TT

Sponsor information

Organisation

University Hospitals Birmingham NHS Foundation Trust (UK)

Sponsor details

Research and Development Office

PO Box 9551

Mindelsohn Way

Queen Elizabeth Medical Centre

Birmingham

England

United Kingdom

B15 2PR

Sponsor type

Hospital/treatment centre

Website

<http://www.uhb.nhs.uk/>

ROR

<https://ror.org/014ja3n03>

Funder(s)

Funder type

Charity

Funder Name

British Heart Foundation (BHF) (UK)

Alternative Name(s)

the_bhf, The British Heart Foundation, BHF

Funding Body Type

Private sector organisation

Funding Body Subtype

Trusts, charities, foundations (both public and private)

Location

United Kingdom

Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date**Individual participant data (IPD) sharing plan****IPD sharing plan summary**

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Protocol article	protocol	06/06/2011		Yes	No
Results article	results	01/03/2015		Yes	No